Xbrane Biopharma partners with JOINN Biologics to develop Darzalex biosimilar Xdarzane

  • Xbrane Biopharma entered a strategic partnership with JOINN Biologics US to develop Xdarzane, its biosimilar candidate to Darzalex (daratumumab).
  • JOINN will handle pilot-scale process development to support analytical similarity to the originator product, targeting commercially viable manufacturing yields.
  • Xbrane will lead global out-licensing to commercial partners, with later stages to include scale-up, clinical development, regulatory filings, and manufacturing.
  • The structure advances the program without additional direct development investment from Xbrane at this stage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xbrane Biopharma AB published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.